Skip to main content

Table 2 Univariate logistic regression on risk of recurrence from 2011 to 2016 (n = 1362)

From: A clinical tool to predict Plasmodium vivax recurrence in Malaysia

Patient characteristic (reference) Recurrence (n = 127) Beta Odds Ratio 95% CI P-value
Age (≥ 27 years) 83 1.00
  < 27 years 44 0.62 1.90 1.14 3.17 0.00
Gender (Female) 52 1.00
 Male 75 0.92 0.40 0.28 0.58 0.00
Malaysian (Non-Malaysians) 16 1.00
 Malaysians 111 1.35 3.87 2.30 6.51 0.00
Region (Non-Western Pacific) 13 1.00
 Western Pacific 114 1.37 3.95 2.28 6.82 0.00
G6PD (Normal) 125 1.00
 Deficient 2 −1.18 0.31 0.07 1.27 0.12
Pregnant (Non-pregnant) 44 1.00
 Pregnant 8 0.89 2.44 1.05 5.66 0.04
Case locality (Urban) 0 1.00
 Rural 104 1.33 3.77 1.89 7.55 0.00
 Agriculture 23 0.70 2.01 0.84 4.77 0.11
Status of case locality (Free) 32 1.00
 Prone 0 −1.08 0.34 0.08 1.43 0.14
 Problematic 95 1.03 2.73 1.78 1.43 0.00
Disease characteristic (reference)
Length of stay (days) (range) 1–14 days −0.01 0.99 0.95 1.04 0.68
Previous infection (no) 97 1.00
 Yes 30 −0.27 0.76 0.48 1.21 0.25
Presence of gametocyte (negative) 37 1.00
 Positive 90 0.24 1.27 0.84 1.92 0.27
Gametocyte (<80 parasite/μL) 44 1.00
  ≥ 80 parasite/μL 83 0.47 1.60 1.07 2.40 0.02
Asexual (<2700 parasite/μL) 60 1.00
  ≥ 2700 parasite/μL 67 0.068 1.07 0.74 1.54 0.71
Week onset (weeks) 1–52 0.00 1.00 0.98 1.01 0.49
Severity (Non-severe) 127 1.00
 Severe infection 0 −18.52 0.00 0.00 . 1.00
Malaria transmission type     
 (Non-indigenous) 10 1.00
 Indigenous 107 1.21 3.35 2.06 5.50 0.00
 Relapse before 10 1.50 4.50 1.82 11.08 0.11
Treatment characteristic (reference)
Treatment type (ACT plus PQ) 106 1.00
 CP plus PQ 21 0.99 2.70 1.66 4.39 0.00
Status of treatment (Complete) 125 1.00
 Incomplete 2 1.445 4.242 0.90 20.02 0.068
  1. ACT Artemisinin-based combination therapies, WHO World Health Organization, G6PD Glucose-6-phosphate dehydrogenase, CP Chloroquine, PQ Primaquine